,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-12-06 05:19:00,Recessions are common enough that you can count on several of them impacting your portfolio over the course of even a 10-year time horizon.,0.03744588792324066,0.22102859616279602,0.7415254712104797,neutral,-0.18358270823955536
1,2017-12-06 05:19:00,"That's just one reason why consumer staples stocks -- businesses that produce essentials such as toothpaste, toilet paper, razors, and diapers -- are so popular among investors.",0.09374024718999863,0.018984736874699593,0.887274980545044,neutral,0.07475551217794418
2,2017-12-06 05:19:00,"In contrast to discretionary products like homes, cars, and restaurant meals, demand for staples holds up even during economic disruptions.",0.8817806839942932,0.04278803616762161,0.07543123513460159,positive,0.8389926552772522
3,2017-12-06 05:19:00,That makes them good stocks to have in your portfolio when those surprise downturns occur.,0.38790175318717957,0.012350545264780521,0.5997477173805237,neutral,0.3755511939525604
4,2017-12-06 05:19:00,The consumer staples industry isn't the place for investors targeting head-turning sales and profit gains.,0.05231189355254173,0.0451386421918869,0.9025494456291199,neutral,0.007173251360654831
5,2017-12-06 05:19:00,"After all, it is a large, mature market that's dominated by just a few players.",0.1241716668009758,0.007057031150907278,0.8687713146209717,neutral,0.11711463332176208
6,2017-12-06 05:19:00,"Sure, innovation plays a part in driving demand for the latest household cleaning or personal care product.",0.2878383696079254,0.00826834887266159,0.7038933038711548,neutral,0.2795700132846832
7,2017-12-06 05:19:00,"But, unlike in the tech world, there isn't much disruption from year to year among industry leaders.",0.029421234503388405,0.5281820893287659,0.4423966705799103,negative,-0.498760849237442
8,2017-12-06 05:19:00,These giants in most cases are cashing in on brands that they've built out over many decades.,0.2266613095998764,0.006699529942125082,0.7666391134262085,neutral,0.21996177732944489
9,2017-12-06 05:19:00,"As a result, consumer staples stocks tend to be slow-growing businesses that generate plenty of excess cash -- money that they mainly give to shareholders through dividend payments and stock repurchase spending.",0.024907415732741356,0.7300669550895691,0.2450256049633026,negative,-0.7051595449447632
10,2017-12-06 05:19:00,"If that sounds like your investing style, you should consider buying Procter & Gamble (NYSE: PG) and/or Johnson & Johnson (NYSE: JNJ) while keeping your distance from Kimberly-Clark (NYSE: KMB) today.",0.09731187671422958,0.009325072169303894,0.8933631181716919,neutral,0.08798680454492569
11,2017-12-06 05:19:00,"Procter & Gamble dominates several huge global consumer categories, with 20% of hair care spending, 25% of the diaper industry, and 25% of the laundry niche spoken for through the Pantene, Pampers, and Tide franchises, respectively.",0.081557497382164,0.005907698534429073,0.9125348329544067,neutral,0.07564979791641235
12,2017-12-06 05:19:00,"And if you bought a razor recently, chances are good that you purchased it from P&G, given that the Gillette, Fusion, Venus, and Mach3 brands account for 65% of the worldwide shaving market.",0.13834163546562195,0.006202526856213808,0.8554558753967285,neutral,0.13213910162448883
13,2017-12-06 05:19:00,That premium position has translated into impressive long-term returns for investors.,0.950459361076355,0.017905443906784058,0.0316350981593132,positive,0.9325538873672485
14,2017-12-06 05:19:00,"P&G turned 15.7% of its sales into earnings last year, which helped fund its 61st consecutive annual dividend increase.",0.9486170411109924,0.018892254680395126,0.03249073028564453,positive,0.9297248125076294
15,2017-12-06 05:19:00,"Be aware, though, that the consumer products titan is facing big challenges.",0.09087154269218445,0.03799951821565628,0.8711289167404175,neutral,0.05287202447652817
16,2017-12-06 05:19:00,"It has posted three consecutive years of declining market share, for example, as value-based competition chips away at its core franchises.",0.018564144149422646,0.9691818356513977,0.012254089117050171,negative,-0.9506176710128784
17,2017-12-06 05:19:00,"However, following a portfolio-slimming transformation, the company is on track for its second straight year of accelerating sales growth.",0.9499707221984863,0.018008597195148468,0.03202071413397789,positive,0.9319621324539185
18,2017-12-06 05:19:00,"Aggressive cost cuts, meanwhile, are providing plenty of room for CEO David Taylor and his executive team to invest in growth initiatives while sending more cash to shareholders.",0.9373753666877747,0.019271820783615112,0.043352849781513214,positive,0.9181035757064819
19,2017-12-06 05:19:00,"For a bit more risk, and potentially higher return, investors should consider Johnson & Johnson stock.",0.4698973000049591,0.013552585616707802,0.5165501236915588,neutral,0.45634472370147705
20,2017-12-06 05:19:00,"Its consumer products segment is anchored by big-name brands like Tylenol, Listerine, and Pepcid.",0.09040775895118713,0.005192776210606098,0.9043994545936584,neutral,0.08521497994661331
21,2017-12-06 05:19:00,"It also includes the iconic Band-Aid franchise that got its start back in 1921, when Johnson & Johnson created the market for commercial dressings on small wounds.",0.1691860407590866,0.005844709929078817,0.8249692320823669,neutral,0.16334132850170135
22,2017-12-06 05:19:00,"Since then, the company has sold over 100 billion Band-Aids.",0.2869907021522522,0.007874301634728909,0.7051350474357605,neutral,0.2791163921356201
23,2017-12-06 05:19:00,"Today, pharmaceutical sales are becoming a larger part of Johnson & Johnson's business, which makes it more susceptible to volatile sales and profit swings.",0.28640851378440857,0.03620452433824539,0.6773869395256042,neutral,0.2502039968967438
24,2017-12-06 05:19:00,"Its fiscal 2011, for example, was negatively impacted by the patent expiration of two blockbuster drugs.",0.018967458978295326,0.9553077220916748,0.025724805891513824,negative,-0.9363402724266052
25,2017-12-06 05:19:00,"However, the combination of smart capital management and a uniquely diverse product portfolio (spanning medical device sales, pharmaceuticals, and consumer products) has ensured that the healthcare titan's returns trounced the broader market over the long term.",0.933215320110321,0.014789032749831676,0.05199560895562172,positive,0.9184262752532959
26,2017-12-06 05:19:00,"With a $9-billion-plus annual commitment to research and development, meanwhile, Johnson & Johnson makes it all but impossible for any company to seriously challenge its position in the healthcare industry.",0.3327504098415375,0.22597837448120117,0.44127121567726135,neutral,0.1067720353603363
27,2017-12-06 05:19:00,"With its Huggies diaper brands sitting just behind P&G's leading Pampers franchise, Kimberly-Clark can't escape comparisons to its larger consumer staples rival.",0.6563745737075806,0.03600362688302994,0.3076218068599701,positive,0.6203709244728088
28,2017-12-06 05:19:00,"Most of those matchups are unfavorable to the runner-up these days, though.",0.03518461063504219,0.8698596358299255,0.094955675303936,negative,-0.8346750140190125
29,2017-12-06 05:19:00,"Whereas Procter & Gamble's sales growth pace is accelerating to a 2.5% rate this year from 2% last year and 1% the year before, Kimberly-Clark is on track for its third straight year of decelerating sales gains.",0.9545544981956482,0.02041122131049633,0.025034276768565178,positive,0.9341433048248291
30,2017-12-06 05:19:00,Organic growth was 5% in 2015 before slipping to 2% last year and coming in roughly flat in fiscal 2017.,0.018475431948900223,0.9477258920669556,0.03379863500595093,negative,-0.9292504787445068
31,2017-12-06 05:19:00,"Kimberly-Clark is also less profitable than P&G despite the fact that its business is heavily tilted toward richer, developed economies like the United States.",0.019611237570643425,0.9474199414253235,0.03296879306435585,negative,-0.9278087019920349
32,2017-12-06 05:19:00,"Finally, the owner of Kleenex tissues is aggressively slicing costs, at a pace of about $400 million per year.",0.7467604279518127,0.023440830409526825,0.22979867458343506,positive,0.7233195900917053
33,2017-12-06 05:19:00,"Yet that doesn't compare to the bold transformation project that led P&G to remove 100 of its weakest brands while reducing spending across its manufacturing, marketing, and supply chain -- and saving an average of $2 billion in each of the last five fiscal years.",0.4744395315647125,0.4139537215232849,0.11160672456026077,positive,0.06048581004142761
34,2017-12-06 05:19:00,Kimberly-Clark executives lowered their sales and profit outlook for the second time this year following disappointing third-quarter results.,0.015816621482372284,0.970201313495636,0.0139820147305727,negative,-0.9543846845626831
35,2017-12-06 05:19:00,"In that report, the company posted just a 1% uptick in sales volume even as prices fell by about the same margin.",0.37740767002105713,0.5773614048957825,0.04523095861077309,negative,-0.19995373487472534
36,2017-12-06 05:19:00,Those trends imply that the company isn't on the cusp of seeing an operating rebound anytime soon.,0.44997647404670715,0.33586862683296204,0.21415495872497559,positive,0.11410784721374512
37,2017-12-06 05:19:00,"Instead, Kimberly-Clark is likely to continue struggling while larger rivals like P&G milk their premium market positioning.",0.03546023741364479,0.9423427581787109,0.022197069600224495,negative,-0.9068825244903564
38,2017-12-06 05:19:00,The above investment ideas each represent a different mix of risk and return potential.,0.028466403484344482,0.0053049977868795395,0.9662285447120667,neutral,0.023161405697464943
39,2017-12-06 05:19:00,"Yet they share a few attractive qualities, including dependable (if minor) sales growth and an elevated pace of cash returns.",0.6827991604804993,0.013175148516893387,0.30402570962905884,positive,0.6696240305900574
40,2017-12-06 05:19:00,"Investors can't bank on innovation revolutionizing the business of either Procter & Gamble or Johnson & Johnson, but they can be reasonably confident that these industry leaders will be around -- and booking higher sales and profits -- decades into the future given that they make so many products that millions of people around the world use every day.",0.6872700452804565,0.019402125850319862,0.29332780838012695,positive,0.66786789894104
41,2017-12-06 05:19:00,"10 stocks we like better than Johnson & Johnson

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen.",0.14497050642967224,0.02279006503522396,0.8322394490242004,neutral,0.12218043953180313
42,2017-12-06 05:19:00,"After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.",0.46925464272499084,0.07301506400108337,0.4577302634716034,positive,0.39623957872390747
43,2017-12-06 05:19:00,"*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them!",0.2519237697124481,0.015385262668132782,0.7326909303665161,neutral,0.23653849959373474
44,2017-12-06 05:19:00,That's right -- they think these 10 stocks are even better buys.,0.8146857619285583,0.02307075634598732,0.16224350035190582,positive,0.7916150093078613
45,2017-12-06 05:19:00,Click here to learn about these picks!,0.0694708302617073,0.055800698697566986,0.8747285008430481,neutral,0.01367013156414032
46,2017-12-06 05:19:00,Demitrios Kalogeropoulos has no position in any of the stocks mentioned.,0.011650554835796356,0.08844966441392899,0.8998997211456299,neutral,-0.07679910957813263
47,2017-12-06 05:19:00,The Motley Fool owns shares of and recommends Johnson & Johnson.,0.03412320837378502,0.015267993323504925,0.9506087303161621,neutral,0.01885521411895752
48,2017-12-06 05:19:00,The Motley Fool has a disclosure policy .,0.016547108069062233,0.01730392687022686,0.9661489725112915,neutral,-0.0007568188011646271
49,2017-12-06 05:19:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
